Health for All
Committed to contribute to global health, at our company, we are dedicated to human progress, and serving patients, scientists, and customers around the globe.
Our scope is to address challenges that affect millions of people, improving the health of underserved populations in low- and middle-income countries through our scientific and technological innovations and products, and the close collaborations with our partners. Our ambition is to serve more than 170 million patients per year in low- and middle-income countries by 2030.
To do that, we drive innovative solutions, partnerships and sustainable business models to address unmet needs across the health value chain, helping to contribute to the United Nations’ 2030 Sustainable Development Goals and supporting our Sustainability Strategy. We aim to create impact for society and sustainable business value for our company.
Our strategic priorities are to: expand access to our healthcare portfolio of products in low- and middle-income countries; catalyze innovative solutions to address global health challenges, including malaria; eliminate schistosomiasis as a public health problem.
We implement our strategy through transformative and sustainable products and technologies, and initiatives to improve healthcare systems. We leverage our core competencies and deliver high-quality, sustainable health solutions to create long-term value.
Our Global Health strategic priorities to fight infectious diseases, schistosomiasis, and malaria, translate into a comprehensive approach that integrates a portfolio of projects for existing treatments, innovative drugs, diagnostics, and preventive measures, as well as initiatives to build capacity in endemic countries. It also covers the entire value chain from research and development throughout registration, to manufacturing and supply, and health systems and access.
Access to Health
To systematically address the many complex factors of access, our engagement to expand access to our health innovations and products translates into a holistic framework organized along three pillars:
Driving the development of solutions to address health challenges, using needs-based Research & Development and responsible Intellectual Property while planning for fastest and broadest access to innovation.
Strengthening health services and infrastructure in low- and middle-income countries to enable patient access to the best possible care.
Implementing innovative mechanisms for equitable and sustainable access to our innovations and products.
Our position in the Top Five of the Access to Medicine Index 2022 demonstrates our firm commitment to Health for All. Our healthcare products for non-communicable diseases reach over 50 Mio patients per year in low-and middle-income countries; in partnership with the World Health Organization, since 2007, we have provided over 1.7 billion tablets of praziquantel and treated 80 Mio patients in 2022, mainly school-aged children, with schistosomiasis.
Access to HealthcareWe enable sustainable access to our solutions to address local needs through collaborative partnerships and a holistic approach to health.Learn more
Access for NTDs
Setting up a new access path, complementary to donations, to extend population reach and move towards long-term sustainability.
Our approach for access to healthcare in low- and middle-income countries at glance.